• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 432627 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1417209734 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1417209734 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Stock Investors Sell Off Shares of Ariad Pharmaceuticals, Down 1.4%

Published on Wed, 01/30/2013 - 13:25
By Adrienne Chilton

One of today's stocks on the move is Ariad Pharmaceuticals (NASDAQ:ARIA), down 1.4% to $20.05. The S&P is currently trading fractionally lower to 1,507 and the Dow Jones Industrial Average is trading fractionally higher to 13,956.

Ariad Pharmaceuticals has overhead space with shares priced $20.05, or 30.1% below the average consensus analyst price target of $28.69. Ariad Pharmaceuticals shares should encounter resistance at the 50-day moving average (MA) of $20.76 and support at its 200-day MA of $19.67.

In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $13.92 and a high of $25.40 and are now at $20.05, 44% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has declined 0.2%.

ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Shares of ConAgra Foods Rise Above Previ...

Shares of ConAgra Foods (NYSE:CAG) traded at a new 52-week high today of $36.58. So fa ...

CACI International: 52-Week High Recentl...

Shares of CACI International (NASDAQ:CACI) traded today at $90.11, breaking its 52-week ...

Watch for Continued Gains in Shares of B...

Boston Properties (NYSE:BXP) traded today at a new 52-week high of $131.15. This new h ...

Brown Shoe Looks to Continue to Trade Ab...

Shares of Brown Shoe (NYSE:BWS) traded at a new 52-week high today of $33.61. This new ...

Buffalo Wild Wings: 52-Week High Recentl...

Buffalo Wild Wings (NASDAQ:BWLD) traded today at a new 52-week high of $171.06. So far ...

Shares of Anheuser-Busch InBev Rise to a...

Anheuser-Busch InBev (NYSE:BUD) traded today at a new 52-week high of $117.47. Approxi ...

Watch for Continued Losses in Shares of ...

Shares of Baytex Energy Trust (NYSE:BTE) traded today at $21.63, breaking its 52-week l ...

Watch for Continued Gains in Shares of B...

Shares of Berkshire Hathaway (NYSE:BRK.B) traded today at $149.49, breaking its 52-week ...